Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis
Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; how...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 2019-07, Vol.129 (7), p.2660-2662 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2662 |
---|---|
container_issue | 7 |
container_start_page | 2660 |
container_title | The Journal of clinical investigation |
container_volume | 129 |
creator | Taylor, Erin B Ryan, Michael J |
description | Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it is not clear how these FLCs drive renal pathology. In this issue of the JCI, Ying et al. unravel a novel mechanism by which FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney. Specifically, FLC-mediated production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1β via induction of capsase-1, and promote activation of TGF-β via αvβ6 integrin. Moreover, the authors identified a tryptophan residue within a specific monoclonal FLC that was required for optimal H2O2 production and downstream signaling. A better understanding of the drivers of MM-associated renal injury has potential for the identification of promising therapeutic targets. |
doi_str_mv | 10.1172/JCI129704 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6597214</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A594318181</galeid><sourcerecordid>A594318181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-43f7f3ee4dcd0afddb96332288c932bd4d08ecd7fbae79eb955277b1874ce62d3</originalsourceid><addsrcrecordid>eNqNkktv1DAUhSMEokNhwR9AkZB4LFL8iMcxC6RqRGFQpUrlsbUc-yZx5dhTOwH673FLGTpoFuguLB1_9_hxT1E8xegIY07efFqtMREc1feKBWasqRpCm_vFAiGCK8Fpc1A8SukCIVzXrH5YHFBMEENkuSjOTyKACWNpk385lcr9UFep7LL4trTjOPvQu9DOzvobsXS2H6ZSD8r6VG5iGMMEZQSvXNnZNoZk0-PiQadcgie362Hx9eT9l9XH6vTsw3p1fFrpJeJTVdOOdxSgNtog1RnTiiWlhDSNFpS0pjaoAW141yrgAlrBGOG8xQ2vNSyJoYfFu9--m7kdwWjwU1RObqIdVbySQVm5u-PtIPvwXS6Z4ATX2eDVrUEMlzOkSY42aXBOeQhzkoQwxEQjEMvo83_QizDH_OobStD89xj9pXrlQFrfhXyuvjaVx0zUFDe5MlXtoXrwkC8ZPHQ2yzv80R4-l4HR6r0Nr3caMjPBz6lXc0py_fn8_9mzb7vsizvsAMpNQwpunmzwaa-pzoFIEbrtUDCS14mV28Rm9tndKW7JPxGlvwBQweJt</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2259370410</pqid></control><display><type>article</type><title>Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Taylor, Erin B ; Ryan, Michael J</creator><creatorcontrib>Taylor, Erin B ; Ryan, Michael J</creatorcontrib><description>Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it is not clear how these FLCs drive renal pathology. In this issue of the JCI, Ying et al. unravel a novel mechanism by which FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney. Specifically, FLC-mediated production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1β via induction of capsase-1, and promote activation of TGF-β via αvβ6 integrin. Moreover, the authors identified a tryptophan residue within a specific monoclonal FLC that was required for optimal H2O2 production and downstream signaling. A better understanding of the drivers of MM-associated renal injury has potential for the identification of promising therapeutic targets.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/JCI129704</identifier><identifier>PMID: 31205026</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Biomedical research ; Bone morphogenetic proteins ; Chain stores ; Cytokines ; Fibrosis ; Freedom ; Humans ; Hydrogen Peroxide ; Hypertension ; Immunoglobulin Light Chains ; Immunoglobulins ; Inflammation ; Integrins ; Janus kinase 2 ; Kidney ; Kidney Diseases ; Light ; Light chains ; Lupus ; Malignancy ; Multiple myeloma ; Novels ; Plasma ; Proteins ; Renal function ; Stat1 protein ; Therapeutic applications ; Transforming growth factors ; Tryptophan</subject><ispartof>The Journal of clinical investigation, 2019-07, Vol.129 (7), p.2660-2662</ispartof><rights>COPYRIGHT 2019 American Society for Clinical Investigation</rights><rights>Copyright American Society for Clinical Investigation Jul 2019</rights><rights>2019 American Society for Clinical Investigation 2019 American Society for Clinical Investigation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-43f7f3ee4dcd0afddb96332288c932bd4d08ecd7fbae79eb955277b1874ce62d3</citedby><cites>FETCH-LOGICAL-c607t-43f7f3ee4dcd0afddb96332288c932bd4d08ecd7fbae79eb955277b1874ce62d3</cites><orcidid>0000-0002-5679-6031 ; 0000-0003-0122-0833</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597214/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597214/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31205026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Taylor, Erin B</creatorcontrib><creatorcontrib>Ryan, Michael J</creatorcontrib><title>Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it is not clear how these FLCs drive renal pathology. In this issue of the JCI, Ying et al. unravel a novel mechanism by which FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney. Specifically, FLC-mediated production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1β via induction of capsase-1, and promote activation of TGF-β via αvβ6 integrin. Moreover, the authors identified a tryptophan residue within a specific monoclonal FLC that was required for optimal H2O2 production and downstream signaling. A better understanding of the drivers of MM-associated renal injury has potential for the identification of promising therapeutic targets.</description><subject>Biomedical research</subject><subject>Bone morphogenetic proteins</subject><subject>Chain stores</subject><subject>Cytokines</subject><subject>Fibrosis</subject><subject>Freedom</subject><subject>Humans</subject><subject>Hydrogen Peroxide</subject><subject>Hypertension</subject><subject>Immunoglobulin Light Chains</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>Integrins</subject><subject>Janus kinase 2</subject><subject>Kidney</subject><subject>Kidney Diseases</subject><subject>Light</subject><subject>Light chains</subject><subject>Lupus</subject><subject>Malignancy</subject><subject>Multiple myeloma</subject><subject>Novels</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Renal function</subject><subject>Stat1 protein</subject><subject>Therapeutic applications</subject><subject>Transforming growth factors</subject><subject>Tryptophan</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkktv1DAUhSMEokNhwR9AkZB4LFL8iMcxC6RqRGFQpUrlsbUc-yZx5dhTOwH673FLGTpoFuguLB1_9_hxT1E8xegIY07efFqtMREc1feKBWasqRpCm_vFAiGCK8Fpc1A8SukCIVzXrH5YHFBMEENkuSjOTyKACWNpk385lcr9UFep7LL4trTjOPvQu9DOzvobsXS2H6ZSD8r6VG5iGMMEZQSvXNnZNoZk0-PiQadcgie362Hx9eT9l9XH6vTsw3p1fFrpJeJTVdOOdxSgNtog1RnTiiWlhDSNFpS0pjaoAW141yrgAlrBGOG8xQ2vNSyJoYfFu9--m7kdwWjwU1RObqIdVbySQVm5u-PtIPvwXS6Z4ATX2eDVrUEMlzOkSY42aXBOeQhzkoQwxEQjEMvo83_QizDH_OobStD89xj9pXrlQFrfhXyuvjaVx0zUFDe5MlXtoXrwkC8ZPHQ2yzv80R4-l4HR6r0Nr3caMjPBz6lXc0py_fn8_9mzb7vsizvsAMpNQwpunmzwaa-pzoFIEbrtUDCS14mV28Rm9tndKW7JPxGlvwBQweJt</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Taylor, Erin B</creator><creator>Ryan, Michael J</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5679-6031</orcidid><orcidid>https://orcid.org/0000-0003-0122-0833</orcidid></search><sort><creationdate>20190701</creationdate><title>Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis</title><author>Taylor, Erin B ; Ryan, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-43f7f3ee4dcd0afddb96332288c932bd4d08ecd7fbae79eb955277b1874ce62d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomedical research</topic><topic>Bone morphogenetic proteins</topic><topic>Chain stores</topic><topic>Cytokines</topic><topic>Fibrosis</topic><topic>Freedom</topic><topic>Humans</topic><topic>Hydrogen Peroxide</topic><topic>Hypertension</topic><topic>Immunoglobulin Light Chains</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>Integrins</topic><topic>Janus kinase 2</topic><topic>Kidney</topic><topic>Kidney Diseases</topic><topic>Light</topic><topic>Light chains</topic><topic>Lupus</topic><topic>Malignancy</topic><topic>Multiple myeloma</topic><topic>Novels</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Renal function</topic><topic>Stat1 protein</topic><topic>Therapeutic applications</topic><topic>Transforming growth factors</topic><topic>Tryptophan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taylor, Erin B</creatorcontrib><creatorcontrib>Ryan, Michael J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taylor, Erin B</au><au>Ryan, Michael J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>129</volume><issue>7</issue><spage>2660</spage><epage>2662</epage><pages>2660-2662</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><abstract>Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with MM present with renal dysfunction at the time of diagnosis. MM-associated renal injury has been linked to an excess level of monoclonal immunoglobulin free light chains (FLCs) in the circulation; however, it is not clear how these FLCs drive renal pathology. In this issue of the JCI, Ying et al. unravel a novel mechanism by which FLCs mediate renal injury in MM by inducing fibrotic and inflammatory pathways in the kidney. Specifically, FLC-mediated production of H2O2 was shown to activate JAK2/STAT1 signaling, increase production of IL-1β via induction of capsase-1, and promote activation of TGF-β via αvβ6 integrin. Moreover, the authors identified a tryptophan residue within a specific monoclonal FLC that was required for optimal H2O2 production and downstream signaling. A better understanding of the drivers of MM-associated renal injury has potential for the identification of promising therapeutic targets.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>31205026</pmid><doi>10.1172/JCI129704</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-5679-6031</orcidid><orcidid>https://orcid.org/0000-0003-0122-0833</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2019-07, Vol.129 (7), p.2660-2662 |
issn | 0021-9738 1558-8238 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6597214 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Biomedical research Bone morphogenetic proteins Chain stores Cytokines Fibrosis Freedom Humans Hydrogen Peroxide Hypertension Immunoglobulin Light Chains Immunoglobulins Inflammation Integrins Janus kinase 2 Kidney Kidney Diseases Light Light chains Lupus Malignancy Multiple myeloma Novels Plasma Proteins Renal function Stat1 protein Therapeutic applications Transforming growth factors Tryptophan |
title | Freedom isn't always free: immunoglobulin free light chains promote renal fibrosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T02%3A10%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Freedom%20isn't%20always%20free:%20immunoglobulin%20free%20light%20chains%20promote%20renal%20fibrosis&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Taylor,%20Erin%20B&rft.date=2019-07-01&rft.volume=129&rft.issue=7&rft.spage=2660&rft.epage=2662&rft.pages=2660-2662&rft.issn=0021-9738&rft.eissn=1558-8238&rft_id=info:doi/10.1172/JCI129704&rft_dat=%3Cgale_pubme%3EA594318181%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2259370410&rft_id=info:pmid/31205026&rft_galeid=A594318181&rfr_iscdi=true |